Oncotarget

Oncotarget

By Oncotarget PodcastScience
Download on the App Store

Oncotarget episodes

  • The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer
    Oncotarget Audiopaper - The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer
    Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=26175&path%5B%5D=81612
    El-Habib Dakir1,2,8, Adam Pickard1, Kirtiman Srivastava1, Cian M. McCrudden3, Stephane R. Gross4, Stephen Lloyd5, Shu-Dong Zhang6, Andriana Margariti7, Richard Morgan8, Philip S. Rudland9 and Mohamed El-Tanani8
    1Center for Cancer Research and Cell Biology, Queen’s University, Belfast, UK
    2Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Salamanca, Spain
    3School of Pharmacy, Queen’s University Belfast, Belfast, UK
    4School of Life and Health Sciences, Aston University, Birmingham, UK
    5School of Medicine, Animal Facility, Queen’s University Belfast, Belfast, UK
    6Northern Ireland Centre for Stratified Medicine, Biomedical Sciences, University of Ulster, UK
    7Center of Experimental Medicine, Queen’s University Belfast, Belfast, UK
    8Institute of Cancer Therapeutics, University of Bradford, Bradford, UK
    9Institute of integrative Biology, University of Liverpool, Liverpool, UK
    Correspondance to:
    El-Habib Dakir, email: [email protected]
    Mohamed El-Tanani, email: [email protected]
    36 min
  • Oncotarget Interview with Professor Mohamed El-Tanani
    Oncotarget Interview with Professor Mohamed El-Tanani
    Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=26175&path%5B%5D=81612
    El-Habib Dakir1,2,8, Adam Pickard1, Kirtiman Srivastava1, Cian M. McCrudden3, Stephane R. Gross4, Stephen Lloyd5, Shu-Dong Zhang6, Andriana Margariti7, Richard Morgan8, Philip S. Rudland9 and Mohamed El-Tanani8
    1Center for Cancer Research and Cell Biology, Queen’s University, Belfast, UK
    2Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, Salamanca, Spain
    3School of Pharmacy, Queen’s University Belfast, Belfast, UK
    4School of Life and Health Sciences, Aston University, Birmingham, UK
    5School of Medicine, Animal Facility, Queen’s University Belfast, Belfast, UK
    6Northern Ireland Centre for Stratified Medicine, Biomedical Sciences, University of Ulster, UK
    7Center of Experimental Medicine, Queen’s University Belfast, Belfast, UK
    8Institute of Cancer Therapeutics, University of Bradford, Bradford, UK
    9Institute of integrative Biology, University of Liverpool, Liverpool, UK
    Correspondance to:
    El-Habib Dakir, email: [email protected]
    Mohamed El-Tanani, email: [email protected]
    29 min
  • Antioxidant Derived From Turmeric May Offer New Treatment Hope For Patients With Advanced Cancers
    Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma
    http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=15744&path[]=50330
    Daniel L. Pouliquen1,2,3, Béatrice Nawrocki-Raby4,5,6, Joëlle Nader1,2,3, Stéphanie Blandin2,7, Myriam Robard2,7, Philippe Birembaut4,5,6,8 and Marc Grégoire1,2,3
    1 INSERM, UMR 1232, Nantes, France
    2 Université de Nantes, Nantes, France
    3 CNRS ERL, Nantes, France
    4 INSERM, UMR-S 903, Reims, France
    5 Université de Reims Champagne-Ardenne, Reims, France
    6 SFR CAP-Santé, Reims, France
    7 Plate-forme MicroPICell, SFR François Bonamy, Nantes, France
    8 Laboratory of Biopathology, CHU Reims, Reims, France
    Correspondence to:
    Daniel L. Pouliquen, email: [email protected]
    6 min
  • Possible New Target For Breast Cancer Treatment
    https://www.rapamycinpress.com/blog/oncotarget/possible-new-target-breast-cancer-treatment/
    Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
    Oncotarget. 2017; 8:20572-20587. https://doi.org/10.18632/oncotarget.16244
    Tristan Gallenne1,9, Kenneth N. Ross4,5,*, Nils L. Visser1,*, Salony4,5,*, Christophe J. Desmet1, Ben S. Wittner4,5, Lodewyk F.A. Wessels2,3, Sridhar Ramaswamy4,5,6,7,8 and Daniel S. Peeper1
    1 Department of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan, CX, Amsterdam, The Netherlands
    2 Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan, CX, Amsterdam, The Netherlands
    3 Faculty of EEMCS Delft University of Technology, Delft, The Netherlands
    4 Massachusetts General Hospital Cancer Center, Boston, MA, USA
    5 Harvard Medical School, Boston, MA, USA
    6 Broad Institute of Harvard & MIT, Cambridge, MA, USA
    7 Harvard Stem Cell Institute, Cambridge, MA, USA
    8 Harvard-Ludwig Center for Cancer Research, Boston, MA, USA
    9 Current address: Merus B.V., Padualaan, CH Utrecht, The Netherlands
    * These authors have contributed equally
    Correspondence to:
    Sridhar Ramaswamy, email: [email protected]
    Daniel S. Peeper, email: [email protected]
    Keywords: breast cancer, metastasis, prognosis, tumor biology
    Received: December 14, 2016 Accepted: January 28, 2017 Published: March 15, 2017
    http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=16244&path[]=51959
    2 min
  • Interview with Francisco Esteva, Adriana Heguy, and Alireza Khodadadi-Jamayran
    Full Text - http://bit.ly/2EJcb1k
    Interview with Francisco Esteva, Adriana Heguy, and Alireza Khodadadi-Jamayran about their paper "Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process."
    Facebook - http://bit.ly/2xznxjV
    Twitter - http://bit.ly/2xzWvsu
    LinkedIn - http://bit.ly/2xzJ6kc
    Pintrest - http://bit.ly/2xzX8SS
    Reddit - http://bit.ly/2hoxI0N
    www.Oncotarget.com
    8 min
  • Research strives to improve the odds for ovarian cancer patients
    Full Text - http://bit.ly/2F4cBLS
    Ovarian cancer is the most lethal of gynecologic cancers in the United States resulting in 14.000 deaths each year. The majority of ovarian cancer arises from fallopian tube or ovarian surface epithelial cells. Despite major differences in the features, all ovarian cancers are treated with surgery followed by chemotherapy.
    Facebook - bit.ly/2xznxjV
    Twitter - bit.ly/2xzWvsu
    LinkedIn - bit.ly/2xzJ6kc
    Pintrest - bit.ly/2xzX8SS
    Reddit - bit.ly/2hoxI0N
    3 min
  • Gene Protein USP11 found to play a role in suppressing DNA damage from cancer causing agents
    Full Text - http://bit.ly/2HDDBn2
    The mechanism called nucleotide excision repair (NER), responsible for protecting our skin and organs from the effects of carcinogens and UV radiation, is poorly understood. In Oncotarget, Volume 8, Issue 57, researchers set out to understand the specific role a gene protein called ubiquitin-specific peptidase 11 (USP11) plays in suppressing DNA damage and the development of tumors.
    Facebook - bit.ly/2xznxjV
    Twitter - bit.ly/2xzWvsu
    LinkedIn - bit.ly/2xzJ6kc
    Pintrest - bit.ly/2xzX8SS
    Reddit - bit.ly/2hoxI0N
    3 min
  • Oncotarget | Interview with Dr. Ken Pienta & Dr. Jim Frost
    Link to YouTube video - http://bit.ly/2HyQX43
    Link to Full Text - http://bit.ly/2BDp3U6
    Oncotarget | Interview with Dr. Ken Pienta and Dr. Jim Frost of Johns Hopkins School of Medicine talking about their experience publishing "Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem."
    Facebook - http://bit.ly/2xznxjV
    Twitter - http://bit.ly/2xzWvsu
    LinkedIn - http://bit.ly/2xzJ6kc
    Pintrest - http://bit.ly/2xzX8SS
    Reddit - http://bit.ly/2hoxI0N
    www.Oncotarget.com
    10 min
  • Spotlight: J. James Frost, cancer pioneer
    Full Text - http://bit.ly/2odFHlK
    Rapamycin Press recently interviewed Dr. J. James Frost, M.D., Ph.D., M.B.A. to discuss his collaborative research paper “Symmetry and Symmetry Breaking in Cancer: A Foundational Approach to the Cancer Problem.”
    Facebook - bit.ly/2xznxjV
    Twitter - bit.ly/2xzWvsu
    LinkedIn - bit.ly/2xzJ6kc
    Pintrest - bit.ly/2xzX8SS
    Reddit - bit.ly/2hoxI0N
    www.Oncotarget.com
    7 min
  • Protein Modification may help explain how prostate cancer spreads
    Full Text - http://bit.ly/2BD4M0Y
    A slight change in a protein can cause prostate cancer cells to become aggressive and invade other parts of the body, a new study found. The research findings, which were published in Oncotarget, provide more insight into the aggressive nature of cancer and could lead to the development of more effective treatments.
    Facebook - bit.ly/2xznxjV
    Twitter - bit.ly/2xzWvsu
    LinkedIn - bit.ly/2xzJ6kc
    Pintrest - bit.ly/2xzX8SS
    Reddit - bit.ly/2hoxI0N
    3 min

About Oncotarget

From the publisher's feed

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.